AveXis offers compelling reasons for a fast FDA OK for gene therapy to treat spinal muscular atrophy in infants – Endpoints News
Endpoints News |
AveXis offers compelling reasons for a fast FDA OK for gene therapy to treat spinal muscular atrophy in infants
Endpoints News But in a small Phase I study of 15 patients treated with AveXis' $AVXS gene therapy for SMA, all of the patients were able to reach 20 months without the need for constant respiratory support, or dying. And many achieved improvements in motor symptoms, … |
